Magnus Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Magnus Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-48,000	Closed	-$22K	–	264
2021 Q3	$22K	Buy	48,000 +8,000	+20%	+$22.8K	﹤0.01%	241
2021 Q2	$4K	Buy	40,000 +20,000	+100%	+$67.3K	﹤0.01%	244
2021 Q1	$10K	Sell	20,000 -32,000	-62%	-$115K	﹤0.01%	231
2020 Q4	$2K	Buy	52,000 +18,400	+55%	+$53.7K	﹤0.01%	355
2020 Q3	$15K	Buy	+33,600	New	+$295K	﹤0.01%	312

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Magnus Financial Group's AKBA Position: Q3 2021 in Review

Magnus Financial Group sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 1,000 shares — an estimated $2.85K sold.

Magnus Financial Group first reported a position in AKBA in Q3 2020 and held it in 2 quarters. The position peaked at $10K in Q3 2020. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

Magnus Financial Group reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
Magnus Financial Group sold 1,000 Akebia Therapeutics shares in Q3 2021, an estimated $2.85K.
Magnus Financial Group first reported a position in Akebia Therapeutics in Q3 2020 and held it in 2 quarters.
Magnus Financial Group's Akebia Therapeutics position peaked at $10K in Q3 2020.
126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Magnus Financial Group's 13F filing for Q3 2021, filed 12 Nov 2021.